The Drugs in Context Archive 2005–2011

Please click on an article to request a FREE FULL TEXT PDF by email.

Price L. UPLIFT – an overview. Understanding Potential Long-term Impacts on Function with Tiotropium. Drugs in Context: e212229. doi: 10.7573/dic.212229

Kassianos G. A summary of the National Institute for Health and Clinical Excellence (NICE) Clinical Guideline 66: the management of type 2 diabetes. Drugs in Context: e212227. doi: 10.7573/dic.212227

Haslam D. Managing obesity and type 2 diabetes: the challenges of guideline implementation. Drugs in Context: e212228. doi: 10.7573/dic.212228

Croom K. A summary of the National Institute for Health and Clinical Excellence (NICE) guidelines on lipid modification. Drugs in Context: e212226. doi: 10.7573/dic.212226

Yawn B. Asmanex Twisthaler: approved in USA for once-daily initiation and maintenance treatment of asthma in children. Drugs in Context: e212222. doi: 10.7573/dic.212222

Croom K. Ezetimibe for the treatment of primary hypercholesterolaemia. Drugs in Context: e212223. doi: 10.7573/dic.212223

Jackson JM. Ivabradine – a novel treatment for chronic stable angina. Drugs in Context: e212225. doi: 10.7573/dic.212225

Adkins J. Ibandronate – a convenient and effective treatment option for the management of post-menopausal osteoporosis. Drugs in Context: e212224. doi: 10.7573/dic.212224

Barham H and Jackson JM. Strontium ranelate – a novel drug for osteoporosis with a dual mechanism of action. Drugs in Context: e212200. doi: 10.7573/dic.212200

Jackson JM. Raltegravir – an integrase inhibitor for antiretroviral therapy in HIV-1 infection. Drugs in Context: e212231. doi: 10.7573/dic.212231

Morrell, J. The key to concordance. Drugs in Context: e212218. doi: 10.7573/dic.212218

Pinkerton S. Improving practice – Bipolar disorder. Drugs in Context: e212208. doi: 10.7573/dic.212208

Bull E and Chambers S. Drug review – Bipolar disorder. Drugs in Context: e212207. doi: 10.7573/dic.212207

Clark R and Chambers S. Disease overview – Bipolar disorder. Drugs in Context: e212206. doi: 10.7573/dic.212206

Cookson J. Editorial – Bipolar disorder. Drugs in Context: e212205. doi: 10.7573/dic.212205

Foster G. Improving practice – Hepatitis C. Drugs in Context: e212201. doi: 10.7573/dic.212201

Clark R. Drug review – Pegasys®. Drugs in Context: e212203. doi: 10.7573/dic.212203

Clark R. Disease overview – Hepatitis C. Drugs in Context: e212202. doi: 10.7573/dic.212202

Bentley I. Editorial – Hepatitis C. Drugs in Context: e212204. doi: 10.7573/dic.212204

Kassianos G. Improving practice – Rotavirus gastroenteritis. Drugs in Context: e212212. doi: 10.7573/dic.212212

Clark R. Drug review – Rotateq®. Drugs in Context: e212211. doi: 10.7573/dic.212211

Clark R. Disease overview – Rotavirus gastroenteritis. Drugs in Context: e212210. doi: 10.7573/dic.212210

Lindley K. Editorial – Rotavirus gastroenteritis. Drugs in Context: e212209. doi: 10.7573/dic.212209

Oxford J. Editorial – Influenza. Drugs in Context (2006) 2(14): 601

Palmer A, Chambers S. Disease overview – Influenza. Drugs in Context (2006) 2(14): 605-617

Higson N. Improving practice – Influenza. Drugs in Context (2006) 2(14): 639-648

Palmer A, Chambers S. Drug review – Oseltamivir. Drugs in Context (2006) 2(14): 619-637

Palmer A. Drug review – Eprosartan. Drugs in Context (2006) 2(13): 573-586

Schachter M. Editorial – Hypertension. Drugs in Context (2006) 2(13): 559

Palmer A, Chambers S. Disease overview – Hypertension. Drugs in Context (2006) 2(13): 561-572

Davis M. Improving practice – Hypertension. Drugs in Context (2006) 2(13): 589-599

Lehman R. Improving practice – Heart failure. Drugs in Context (2006) 2(4): 171-179

Price D. Editorial – Allergic rhinitis and asthma. Drugs in Context (2006) 2(10): 415

Finn A. Editorial – Pneumococcal infections. Drugs in Context (2006) 2(11): 459

Chambers S. Disease overview – Pneumococcal infections. Drugs in Context (2006) 2(11): 461-473

Kassianos G. Improving practice – Pneumococcal infections. Drugs in Context (2006) 2(11): 493-502

Chambers S. Drug review – Prevenar. Drugs in Context (2006) 2(11): 475-491

Parkinson C. Editorial – Acromegaly. Drugs in Contex (2006) 2(9): 379

Roberts M. Improving practice – Acromegaly. Drugs in Context (2006) 2(9): 407-410

Palmer A. Disease overview – Acromegaly. Drugs in Context (2006) 2(9): 381-389

Palmer A. Drug review – Pegvisomant. Drugs in Context (2006) 2(9): 391-405

Palmer A. Drug review – Insulin glargine. Drugs in Context (2006) 2(8): 349-365

Home P. Editorial – Diabetes. Drugs in Context (2006) 2(8): 335

Clark R, Palmer A. Disease overview – Diabetes. Drugs in Context(2006) 2(8): 337-347

Hughes E. Improving practice – Diabetes. Drugs in Context (2006) 2(8): 367-374

Palmer A. Drug review – Candesartan. Drugs in Context (2006) 2(4): 153-169

McMurray JJV. Editorial – Heart failure. Drugs in Context (2006) 2(4): 139

West D. Disease overview – Heart failure. Drugs in Context (2006) 2(4): 141-150

Palmer A. Drug review – Anastrazole. Drugs in Context (2006) 2(7): 305–321

Baum M. Editorial – Breast cancer. Drugs in Context (2006) 2(7): 283–4

Palmer A. Disease overview – Breast cancer. Drugs in Context (2006) 2(7): 285–303

Jones A. Improving practice – Breast cancer. Drugs in Context (2006) 2(7): 323-330

Ryan D. Improving practice – Allergic rhinitis and asthma. Drugs in Context (2006) 2(10): 445-453

Fox-Spencer R. Disease overview – Allergic rhinitis and asthma. Drugs in Context (2006) 2(10): 417-427

Fox-Spencer R. Drug review – Montelukast. Drugs in Context (2006) 2(10): 429-444

Chapple C. Editorial – Urinary incontinence. Drugs in Context (2006) 2(3): 87

Bull E. Disease overview – Urinary incontinence. Drugs in Context (2006) 2(3): 89–101

Kirby M. Improving practice – Urinary incontinence. Drugs in Context (2006) 2(3): 127–135

Palmer A. Drug review – Tolterodine. Drugs in Context (2006) 2(3): 103–124

Dowson A. Editorial – Neuropathic pain. Drugs in Context (2006) 2(2): 51

Bull E. Disease overview – Neuropathic pain. Drugs in Context (2006) 2(2): 53-63

Rasmussen J. Improving practice – Neuropathic pain. Drugs in Context (2006) 2(2): 79-84

Travis M. Editorial – Schizophrenia. Drugs in Context (2006) 2(5): 183

Clark R. Disease overview – Schizophrenia. Drugs in Context (2006) 2(5): 184-192

Rasmussen J. Improving practice – Schizophrenia. Drugs in Context (2006) 2(5): 220-227

Clark R, Palmer A, Chambers S. Drug review – Olanzapine. Drugs in Context (2006) 2(5): 193-217

Bull E. Drug review – Pregabalin. Drugs in Context (2006) 2(2): 65-77

Palmer A. Drug review – Duloxetine. Drugs in Context (2005) 1(25): 1265–1284

Cowen PJ. Editorial – Depression. Drugs in Context (2005) 1(25): 1251

Clark R, Bull E. Disease overview – Depression. Drugs in Context (2005) 1(25): 1253–1263

Kassianos G. Improving practice – Depression. Drugs in Context (2005) 1(25): 1285–96

Brady A. Editorial – Hypertension and cardiovascular disease. Drugs in Context (2006) 2(1): 3

Moorman J, West D, Chambers S. Disease overview – Hypertension and Cardiovascular disease. Drugs in Context (2006) 2(1): 5-15

Morrell J. Improving practice – Hypertension and cardiovascular disease. Drugs in Context (2006) 2(1): 41-48

West D, Chambers S. Drug review – Perindopril. Drugs in Context (2006) 2(1): 17-39

Bull E, Chambers S. Drug review – Finasteride. Drugs in Context (2005) 1(21): 1051-1069

Fox-Spencer R. Drug review – Alfuzosin. Drugs in Context (2005) 1(22): 1095–1115

Boustead G. Editorial – Benign prostatic hyperplasia (BPH). Drugs in Context (2005) 1(22): 1083

Clark R. Disease overview – Benign prostatic hyperplasia (BPH). Drugs in Context (2005) 1(22): 1085–1094

Barclay C, Chapple C. Improving practice – Benign prostatic hyperplasia (BPH). Drugs in Context (2005) 1(22): 1117–1123

Speakman MJ. Editorial – Benign prostatic hyperplasia (BPH). Drugs in Context (2005) 1(21): 1039

Zuckerman J. Editorial – Hepatitis A and B. Drugs in Context (2005) 1(24): 1167–1168

Fox-Spencer R. Disease overview – Hepatitis B. Drugs in Context (2005) 1(24): 1179–1190

Bull E. Disease overview – Hepatitis A. Drugs in Context (2005) 1(24): 1169–1177

Kassianos G. Improving practice – Hepatitis A and B. Drugs in Context (2005) 1(24): 1215–1247

Fox-Spencer R. Drug review – Twinrix. Drugs in Context (2005) 1(24): 1193–1211

Enright P. Editorial – Asthma. Drugs in Context (US) (2005) 1(7): 277–320

Yawn B. Improving practice – Asthma. Drugs in Context (US) (2005) 1(7): 309–319

Pittard J. Improving practice – Angina. Drugs in Context (2003) 1 (16): 31–35

Bull E, Elward K. Disease overview – Asthma. Drugs in Context (US) (2005) 1(7): 281–294

Chambers S, Chambers S, Uden D. Drug review – Mometasone. Drugs in Context (US) (2005) 1(7): 295–308

Halpin D. Editorial – COPD. Drugs in Context (2005) 1(20): 991

Chambers S, Chambers S. Disease overview – COPD. Drugs in Context (2005) 1(20): 993-2004

Jones R. Improving practice – COPD. Drugs in Context (2005) 1(20): 1024–1034

Fox-Spencer R. Drug review – Seretide. Drugs in Context (2005) 1(20): 1005-1023

Bull E. Drug review – Levetiracetam. Drugs in Context (2005) 1(23): 1143-1155 Editorial – Epilepsy

Lawthom C, Smith P. Editorial – Epilepsy. Drugs in Context (2005) 1(23): 1127

Bull E. Disease overview – Epilepsy. Drugs in Context (2005) 1(23): 1129-1142

Smithson H. Improving practice – Epilepsy. Drugs in Context (2005) 1(23): 1157-1164

Rudolph M. Improving practice – COPD. Drugs in Context (2005) 1(19): 987-988

Fox-Spencer R. Drug review – Symbicort. Drugs in Context (2005) 1(19): 965-978

Rudolph M. Editorial – COPD. Drugs in Context (2005) 1(19): 951

Moorman J, West D, Palmer A. Drug review – Irbesartan. Drugs in Context (2005) 1(18): 917-937

Stone M. Editorial – Osteoporosis. Drugs in Context (2005) 1(16): 799

Williams B. Editorial – Hypertension. Drugs in Context (2005) 1(18): 903

Palmer A. Drug review – Alendronate. Drugs in Context (2005) 1(16): 813-838

Bull E. Disease overview – Osteoporosis. Drugs in Context (2005) 1(16): 801-812

Brown P. Improving practice – Osteoporosis. Drugs in Context (2005) 1(16): 841-849

Reckless JPD. Editorial – Type 2 diabetes. Drugs in Context (2005) 1(14): 723

Clark R. Disease overview – Type 2 diabetes. Drugs in Context (2005) 1(14): 725–732

Bull E. Drug review – Metformin. Drugs in Context (2005) 1(14): 733–751

Palmer A. Drug review – Lamotrigine. Drugs in Context (2005) 1(12): 647-665

Leach JP. Editorial – Epilepsy. Drugs in Context (2005) 1(12): 631

Mortimer AM. Editorial – Schizophrenia. Drugs in Context (2005) 1(13): 679

Palmer A. Drug review – Quetiapine. Drugs in Context (2005) 1(13): 691-711

Bull E. Drug review – Formoterol. Drugs in Context (2005) 1(4): 171–187

Bull E. Drug review – Budesonide. Drugs in Context (2005) 1(4): 151–168

Haughney J. Editorial – Asthma. Drugs in Context (2005) 1(4): 136

Bull E. Drug review – Symbicort. Drugs in Context (2005) 1(4): 189–207

Palmer A. Drug review – Fluticasone. Drugs in Context (2005) 1(5): 235-255

Ryan D. Editorial – Asthma. Drugs in Context (2005) 1(5): 220

Bull E. Disease overview – Asthma. Drugs in Context (2005) 1(5): 221-234

Palmer A. Drug review – Seretide. Drugs in Context (2005) 1(5): 277-300

Palmer A. Drug review – Salmeterol. Drugs in Context (2005) 1(5): 257-275

Barnett A. Editorial – Type 2 diabetes. Drugs in Context (2005) 1(10): 535

Palmer A. Drug review – Pioglitazone. Drugs in Context (2005) 1(10): 545–567

Chambers S, Yawn R. Drug review – Clopidogrel. Drugs in Context (US) (2005) 1(5): 207–228

Bursi F. Editorial – Atherothrombosis. Drugs in Context (US) (2005) 1(5): 191–192

Chambers S, Yawn R. Disease overview – Atherothrombosis. Drugs in Context (US) (2005) 1(5): 193–206

Sinsky CA. Improving practice – Atherothrombosis. Drugs in Context (US) (2005) 1(5): 229–236

Gruffydd-Jones K. Improving practice – Asthma. Drugs in Context (2005) 1(5): 303-309

Fox-Spencer R. Drug review – Fluticasone. Drugs in Context (2005) 1(11): 591-618

Ryan D, Price D. Editorial – Allergic rhinitis. Drugs in Context (2005) 1(11): 579

Kassianos G. Improving practice – Allergic rhinitis. Drugs in Context (2005) 1(11): 621-625

MacGregor A. Editorial – Migraine. Drugs in Context (2005) 1(8): 447

West D. Disease overview – Migraine. Drugs in Context (2005) 1(8): 449–463

Gruffydd-Jones K. Improving practice – Migraine. Drugs in Context (2005) 1(8): 487–493

Bull E. Drug review – Sumatriptan. Drugs in Context (2005) 1(8): 465–484

Ford L, Beeching N. Editorial – Hepatitis A and Typhoid fever. Drugs in Context (2005) 1(6): 315–6

Bull E. Drug review – Avaxim. Drugs in Context (2005) 1(6): 349-355

Fox-Spencer R. Disease overview – Typhoid fever. Drugs in Context (2005) 1(6): 327-335

Kassianos G. Improving practice – Typhoid and combination vaccines. Drugs in Context (2005) 1(6): 383-392

Kassianos G. Improving practice – Hepatitis A. Drugs in Context (2005) 1(6): 369-382

Fox-Spencer R. Drug review – ViATIM. Drugs in Context (2005) 1(6): 337-346

Fox-Spencer R. Drug review – Typhim Vi. Drugs in Context (2005) 1(6): 357-366

Bull E. Drug review – Fexofenadine. Drugs in Context (2005) 1(9): 511-525

Howarth P. Editorial – Allergic rhinitis. Drugs in Context (2005) 1(9): 499

Clark R. Disease overview – Allergic rhinitis. Drugs in Context (2005) 1(11): 581-590

Green LA. Editorial – Hypertension and cardiovascular disease. Drugs in Context (US) (2005) 1(3): 95–96

Clark R. Disease overview – Bipolar disorder. Drugs in Context (2005) 1(2): 45-56

Travis MJ. Editorial – Bipolar disorder. Drugs in Context (2005) 1(2): 43

Bull E. Drug review – Memantine. Drugs in Context (2005) 1(1): 17-27

Wilkinson D. Editorial – Alzheimer’s disease. Drugs in Context (2005) 1(1): 3

Greaves I. Improving practice – Alzheimer’s disease. Drugs in Context (2005) 1(1): 29-37

Clark R. Disease overview – Alzheimer’s disease. Drugs in Context (2005) 1(1): 5-16

Clark R. Drug review – Quetiapine. Drugs in Context (2005) 1(2): 57-76